EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial

Takuji Iwase iD, Shigehira Saji, Kotaro Iijima iD, Kenji Higaki, Shoichiro Ohtani, Yasuyuki Sato, Yasuo Hozumi, Yoshie Hasegawa, Yasuhiro Yanagita, Hiroyuki Takei, Maki Tanaka, Hideji Masuoka und 6 weitere

Journal of Clinical Oncology · 20.06.2023 · 41 (18) · 3329-3338

DOI: 10.1200/jco.22.00577 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.06.2023. Verfasst von Takuji Iwase und 17 weiteren Autor:innen. Beteiligte Einrichtung: Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasms, Second Primary. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Treatment with an aromatase inhibitor for 5 years is the standard treatment for postmenopausal hormone receptor–positive breast cancer. We investigated the effects of extending this treatment to 10 years on disease-free survival (DFS). PATIENTS AND METHODS This prospective, randomized, multicenter open-label phase III study assessed the effect of extending anastrozole treatment for an additional 5 years in postmenopausal patients who were disease-free after treatment with either 5 years of anastrozole alone or 2-3 years of tamoxifen followed by 2-3 years of anastrozole. Patients were allocated randomly (1:1) to continue anastrozole for an additional 5 years or stop anastrozole. The primary end point was DFS, including breast cancer recurrence, second primary cancers, and death from any cause. This study is registered with University Hospital Medical Information Network, Japan (UMIN) clinical trials registry (UMIN000000818). RESULTS We enrolled 1,697 patients from 117 facilities between November 2007 and November 2012. Follow-up information was available for 1,593 patients (n = 787 in the continue group, n = 806 in the stop group), who were defined as the full analysis set, including 144 patients previously treated with tamoxifen and 259 patients who underwent breast-conserving surgery without irradiation. The 5-year DFS rates were 91% (95% CI, 89 to 93) in the continue group and 86% (95% CI, 83 to 88) in the stop group (hazard ratio, 0.61; 95% CI, 0.46 to 0.82; P < .0010). Notably, extended anastrozole treatment reduced the incidence of local recurrence (continue group, n = 10; stop group, n = 27) and second primary cancers (continue group, n = 27; stop group, n = 52). There was no significant difference in overall or distant DFS. Menopausal or bone-related all-grade adverse events were more frequent among patients in the continue group than those in the stop group, but the incidence of grade ≥3 adverse events was

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasms, Second PrimaryHumansFemaleAnastrozoleProspective StudiesNitrilesTriazolesNeoplasm Recurrence, LocalTamoxifenAromatase InhibitorsDisease-Free SurvivalAdjuvants, ImmunologicAntineoplastic Agents, HormonalChemotherapy, Adjuvant

Substanzen

AnastrozoleNitrilesTriazolesTamoxifenAromatase InhibitorsAdjuvants, ImmunologicAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
  • Fukushima Medical University, Fukushima, Japan.
  • Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • University of Tsukuba Hospital/Ibaraki Prefectural Central Hospital, Kasama, Japan.

ORCID-Profile: Takuji Iwase, Kotaro Iijima, Masahiko Tanabe, Hiroshi Ohtsu, Hirofumi Mukai

Zitieren

APA

Iwase, T., Saji, S., Iijima, K., Higaki, K., Ohtani, S., Sato, Y., Hozumi, Y., Hasegawa, Y., Yanagita, Y., Takei, H., Tanaka, M., Masuoka, H., Tanabe, M., Egawa, C., Komoike, Y., Nakamura, T., Ohtsu, H., & Mukai, H. (2023). Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. Journal of Clinical Oncology, 41(18), 3329-3338. https://doi.org/10.1200/jco.22.00577

Vancouver

Iwase T, Saji S, Iijima K, Higaki K, Ohtani S, Sato Y, et al. Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. Journal of Clinical Oncology. 2023;41(18):3329-3338. doi:10.1200/jco.22.00577

BibTeX
@article{Iwase2023,
  author = {Iwase, Takuji and Saji, Shigehira and Iijima, Kotaro and Higaki, Kenji and Ohtani, Shoichiro and Sato, Yasuyuki and Hozumi, Yasuo and Hasegawa, Yoshie and Yanagita, Yasuhiro and Takei, Hiroyuki and Tanaka, Maki and Masuoka, Hideji and Tanabe, Masahiko and Egawa, Chiyomi and Komoike, Yoshifumi and Nakamura, Toshitaka and Ohtsu, Hiroshi and Mukai, Hirofumi},
  title = {Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {18},
  pages = {3329--3338},
  doi = {10.1200/jco.22.00577}
}
Kostenlos starten →